Navigation Links
Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
Date:2/3/2009

SOUTH SAN FRANCISCO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will delay further partnership discussions regarding R788 until after results from the Phase 2b clinical trials of R788 are available. The company expects that these results, involving approximately 650 additional patients, will substantially further the understanding of R788's potential and may therefore drive enhanced economics in a possible deal. The company expects to have a collaboration partnership in place prior to initiating Phase 3 clinical trials. Enrollment in the two Phase 2b clinical trials of R788, TASKi2 and TASKi3, are ahead of schedule and the results from these clinical trials are expected to be available in July and August 2009, respectively. In addition, analysis of the recently completed QT/QTc safety study has confirmed that R788 does not elicit a QT/QTc signal.

The company also announced that it has cut its research programs in virology and oncology as well as certain related development and administrative staff, which resulted in the dismissal of 36 employees or approximately 20% of the company's workforce. This measure is intended to maintain the company's emphasis on its active preclinical and clinical programs, while conserving the company resources. The company is still assessing the restructuring and other charges associated with this measure, which is expected to be predominantly recorded in the first quarter of 2009. As of December 31, 2008, the company had $134.5 million in cash, cash equivalents and available-for-sale securities, which the company believes is enough for it to maintain its current development priorities through the second quarter of 2010.

"We have decided that postponing the partnership for R788, pending the forthcoming clinical tri
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
2. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
3. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
6. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
7. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
8. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
9. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
10. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)...  Over the next five years, the marijuana industry in ... predicting that 14 more states will legalize recreational marijuana and ... for legal cannabis grew 74 percent in 2014 to $2.7 ... market could grow more than fourfold to $11 billion in ... on marijuana. Cannabiz Mobile Inc. (OTCBB: LGBI) is ...
(Date:4/17/2015)... DUBLIN , Apr. 16, 2015 Research and ... addition of the "Corporate Reputation of Pharma in ... 2nd edition" report to their offering. ... perspectives from 130 patient groups with an interest in ... companies (and of the pharma industry as a whole) ...
(Date:4/17/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ... Reputation of Pharma in 2014 - a Perspective of ... to their offering. For the first time, ... corporate reputation of the pharmaceutical industry held by patient ... views of patient organisations representing all therapy areas. ...
Breaking Medicine Technology:Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3
... PRUSSIA, Pa., May 1, 2012  Medical Alarm Concepts Holding, ... agreement with several holders of its convertible debt. Under ... has been cancelled, preventing a significant amount of common ... of another 13,750,000 million warrants, bringing the total number ...
... Acella Pharmaceuticals, LLC, announces the addition of Tom ... of their commercial team. Tom will lead the ... line.    Tom is a highly ... than 11 years of industry experience, including sales, ...
Cached Medicine Technology:MDHI in Agreement with Debt Holders - Portion of Convertible Debt and Additional 14M Warrants Cancelled -- Total of 101M Warrants Cancelled this Year 2
(Date:4/18/2015)... Beverly Hills, CA (PRWEB) April 19, 2015 ... cherish and will proudly display for the rest of their ... and money obtaining them and put in a great amount ... gotten on a whim, they have outgrown them or simply ... 20 percent of people regret their tattoo, and in 2012-13 ...
(Date:4/18/2015)... released a new blog post explaining how to find ... damage. , Clients can now find auto insurance plans ... intentionally on fire. This type of damages can be linked ... , It is possible to compare the best online car ... in just a few minutes. Clients should always review multiple ...
(Date:4/18/2015)... Lowcostcarinsuranceprice.com has released a new blog post explaining ... insurance prices . , Drivers who live in ... have to pay more for auto insurance plans that ... also offer protection against vehicle theft. , Affordable ... a single website: http://lowcostcarinsuranceprice.com/ . Drivers who ...
(Date:4/18/2015)... More than 2000 styles of newly designed ... #1 online store carrying celebrity inspired special occasion dresses. ... their perfect dresses for their prom. For those who ... at TheCelebrityDresses.com would be an ideal choice. , ... dresses inspired by the most loved styles seen at ...
(Date:4/18/2015)... Canada (PRWEB) April 18, 2015 French ... emotions on food choices when he uttered, “Tell me ... you are.” Using food to cope with stress or ... by Queendom.com indicates otherwise. Data collected from ... genders fall victim to emotional eating, but for different ...
Breaking Medicine News(10 mins):Health News:Dennis Dass, M.D. is Shattering the Past While Revealing the Future 2Health News:Online Auto Insurance Quotes For Plans That Cover Fire Damages! 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6
... , , More than 45 million Americans suffer from headaches ... up with the National Headache Foundation (NHF), EHE International is helping ... annually. In a unique approach, the NHF and EHE are ... 115 square-foot display window at 10 Rockefeller Plaza, for the month ...
... CVD ) today announced that it will present at William ... 9, 2009 at 4:50 p.m. (ET). Investors may access ... . In order to register and download any necessary software, ... Covance, with headquarters in Princeton, New Jersey, is one of the ...
... groups issued the following statement regarding the upcoming FDA ... , As advocates for people living with mental ... the importance of viable treatment options for bipolar disorder ... to safe and effective treatments, including more information about ...
... under-represented in clinical cancer research published in high-impact journals, ... University of Michigan Comprehensive Cancer Center. Taking into ... women, studies included a smaller proportion of women than ... of cancer types that were not gender specific, including ...
... Continua Health Alliance Design Guidelines , , SAN ... ZigBee(R) Alliance announced today that the Continua Health Alliance ... power local area network (LAN) standard. ZigBee Health Care ... a single network. Continua recommends ZigBee for sensing and ...
... Pa., June 8 ViroPharma Incorporated (Nasdaq: VPHM ... to its board of directors. , , Dr. Baldino ... and leadership to ViroPharma. He is the chief executive ... Inc., an international biopharmaceutical company in Chester County, Pennsylvania. ...
Cached Medicine News:Health News:EHE International Supports the National Headache Foundation 2Health News:Joint Statement on Atypical Antipsychotic Use in Children 2Health News:Joint Statement on Atypical Antipsychotic Use in Children 3Health News:Women underrepresented in cancer research, U-M study finds 2Health News:ZigBee Selected by Continua Health Alliance for Next Generation Guidelines 2Health News:ZigBee Selected by Continua Health Alliance for Next Generation Guidelines 3Health News:ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors 2Health News:ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors 3
Inquire...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
... The new Finnpipette Focus from ... to combine ergonomics with uncompromising ... handle plate offers a custom ... The new shorter tip cones ...
Medicine Products: